Signum Biosciences
About Signum STM Platform Pipeline Partners Careers News & Events Investors
Learn more about our STM platform
 
 

In the Lab

 

In the Market

 

Join Us

Interested in a job at Signum? Visit our job postings section for a listing of our open positions.
 
 
Signum has identified and isolated SIG1012, the PPM molecule in coffee. We have synthesized this small molecule and are currently assessing its activity in a mouse model of type II diabetes. Cell-based assays are also being performed to assess the effect of SIG1012 on Tau phosphorylation (a key protein in Alzheimer’s Disease).
 

We have entered into a joint development license and commercialization agreement with Rohto Pharmaceutical Co., Ltd, for the development and commercialization of our proprietary technologies in the Japanese market.

   
           
 
In collaboration with the University of Pennsylvania, we are investigating the effects of Arazine compounds in a mouse model of asthma.
 

Signum is granted INCI approval of Arazine as well as STMs as a new class of cosmetic ingredients. Our GPM technology has exciting applications in skin care and cosmetics.

   
           
 

Latest News

   
 

Jun 2008

Kunio Yamada of Rohto Pharmaceuticals joins Signum’s Board of Directors. Read more

April 2008
Signum opens Series A-3 financing round for $3 million. Read more

March 2008
Signum Biosciences expands to accommodate our company's rapid growth. Read more

March 2008
Signum Biosciences research findings published in the Journal of Investigative Dermatology. Read more

   
 
 
Site map   |   Contact Us   |   Privacy Policy   |   Terms of Use   |   © Signum Biosciences, Inc., All Rights Reserved.